156 related articles for article (PubMed ID: 2057989)
1. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
[TBL] [Abstract][Full Text] [Related]
2. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
4. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.
Lönnerholm G; Kreuger A; Lindström B; Myrdal U
Pediatr Hematol Oncol; 1989; 6(2):105-12. PubMed ID: 2702064
[TBL] [Abstract][Full Text] [Related]
5. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
[TBL] [Abstract][Full Text] [Related]
6. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
[TBL] [Abstract][Full Text] [Related]
10. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.
Lafolie P; Björk O; Hayder S; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1989; 6(4):259-65. PubMed ID: 2615529
[TBL] [Abstract][Full Text] [Related]
11. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia.
Jacqz-Aigrain E; Nafa S; Médard Y; Bessa E; Lescoeur B; Vilmer E
Eur J Clin Pharmacol; 1997; 53(1):71-4. PubMed ID: 9349933
[TBL] [Abstract][Full Text] [Related]
13. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
15. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
[TBL] [Abstract][Full Text] [Related]
16. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia--interindividual and intraindividual variations].
Hijiya N; Kato Y; Matsushita T; Yokoyama T
Rinsho Ketsueki; 1989 Nov; 30(11):1931-6. PubMed ID: 2607612
[TBL] [Abstract][Full Text] [Related]
18. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
Hayder S; Björk O; Lafolie P
Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
[TBL] [Abstract][Full Text] [Related]
19. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
20. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
Hale JP; Lilleyman JS
Arch Dis Child; 1991 Apr; 66(4):462-6. PubMed ID: 2031601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
